Drugs / CER-1236
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06834282 | Apr 2025 → Dec 2026 expected | acute myeloid leukemia | CERo Therapeutics Holdings, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CER-1236 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06834282 ↗ |
| Modality | Cell therapy | “CER-1236 is a first in class chimeric engulfment receptor T-cell therapy candidate” NCT06834282 ↗ |